Microbiotica presented positive Phase 1b trial results for MB097, a precision microbiome therapy combined with KEYTRUDA, in advanced melanoma patients resistant to anti-PD-1 therapy. The trial showed MB097 was safe, well tolerated, and led to significant tumor reduction, especially in patients pre-treated with vancomycin. These findings suggest MB097 may help restore sensitivity to immunotherapy in difficult cases and support further clinical studies. The trial involved 41 patients across Europe and met all primary and secondary endpoints.
Microbiotica's Phase 1b clinical data presentation on MB097 offers context for health sector investors. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 26, 2026 14:11 WIB: out of 150 priced US health stocks, 76 rose and 66 fell. Notable movers include ENVB at USD 1.40 (-7.28%), AMLX at USD 27.20 (-6.30%), and NUWE at USD 0.35 (+6.09%).
Norsk Hydro has announced its Investor Day event scheduled for November 25, 2026, in London, with an option to join virtually. The event will feature presentations and Q&A sessions with the CEO and CFO, followed by a roundtable exclusively for sell-s...
STMicroelectronics has introduced the first combination sensors for automotive safety aimed at mass-market vehicles, integrating multi-axis accelerometers and gyroscopes in one package. These sensors support advanced safety features like crash protec...
Norsk Hydro has announced an investor day event scheduled for November 25, 2026, in London at 30 Euston Square. The event will feature presentations and Q&A sessions with the CEO and CFO, followed by lunch and roundtable discussions exclusively for s...
Barmeter Technologies highlighted research by Harsha Nooka on AI-generated front-end code accessibility. The study introduced AXIS-Bench, a benchmark testing if AI-created web components meet accessibility standards for keyboard users and assistive t...
Barmeter Technologies spotlighted Sai Kumar Pola's 2026 research on autonomous warehouse robot task management, showing adaptive methods improve order completion and recovery from disruptions in simulations. Pola also co-invented a 2023 U.S. patent f...
